Abstract: A conditioning process that is employed with a high selectivity catalyst (HSC) during an initial phase (i.e., start-up) of the epoxidation process is provided. The HSC conditioning process of the present disclosure ensures that the heat release from a catalyst bed containing an HSC during a start-up operation is less than 2000 kJ/Kgcat·hr. The HSC containing catalyst bed that has been conditioned by the process of the present disclosure exhibits improved performance (i.e., EO selectivity) and reduced hot spots.

Abstract: A 12-bromo-2,16-dioxapentacyclo[7.7.5.01,21.03,8.010,15]henicosa3(8),10,12,14-tetraene-7,20-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.

Abstract: The present invention relates to novel use of koumine, an alkaloid monomer from Gelsemium elegans Benth., or a pharmaceutically acceptable salt thereof, and more particularly to use of koumine or its pharmaceutically acceptable salt in the preparation of a medicament for the treatment of inflammatory bowel disease.

Abstract: An 9-(2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3,6-diphenyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.

Abstract: A compound 1,3-benzothiazol-2-yl-N?-(benzoyloxy)ethanimidamide, its synthesis, and its use as an anticancer and/or antimicrobial agent.

Abstract: Processes and systems for producing olefin epoxides with three or more carbon atoms by oxidation of the corresponding branched hydrocarbons using oxygen are disclosed. An example process for producing olefin epoxides may include oxidizing a branched alkane to produce at least an organic hydroperoxide. The example process may further include epoxidizing a branched alkene by a catalytic reaction with least a portion of the organic hydroperoxide to produce at least an olefin epoxide and an alcohol. The example process may further include converting at least a portion of the alcohol to either additional branched alkane and/or additional branched alkene.

Abstract: A N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The disclosure is directed to a beverage sachet including a powder which includes protocatechuic acid, an electrolyte, and a sweetener. The sachet can further include a cannabinoid. The cannabinoid may be cannabidiol. The electrolyte may include sodium chloride salt or monopotassium phosphate salt. The sachet may further include vitamin C, vitamin D, a B vitamin, magnesium, or calcium. The sweetener may include sucrose, glucose, dextrose, maltodextrins, or fructose. The disclosure also includes a beverage including protocatechuic acid and a cannabinoid. The cannabinoid may be cannabidiol. The beverage may be a sports beverage including sweeteners and electrolytes. The beverage may be a health beverage including a fruit, a vegetable, vitamin C, vitamin D, a B vitamin, magnesium, or calcium.

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3K?). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3K? activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

Abstract: The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same.

Abstract: A field of asymmetric catalytic synthesis, and in particular a preparation method for a high optical indoxacarb intermediate includes reacting 5-chloro-2-methoxycarbonyl-1-indanone ester (or indanone ester for short) with an oxidizing agent in the presence of a chiral Zr-salen polymer to obtain an indoxacarb intermediate (2S)-5-chloro-2,3-dihydro-2-hydroxy-1-oxo-1H-indole-2-carboxylic acid methyl ester. The yield is stabilized between 86% and 90%, and the S-enantiomer content is up to 99%. Such catalyst can replace catalysts such as cinchonine, and greatly increase the content of the effective S-enantiomer of the indoxacarb, so that the content of the hydroxyl intermediate S-enantiomer of the indoxacarb is raised from 75% to 99% or more. In addition, the chiral Zr-salen polymer catalyst is recycled without retreatment, and can be recycled at least 5 times or more, greatly reducing the production cost and laying a foundation for the industrial production of high quality indoxacarb.

Abstract: Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Abstract: A process for making propene oxide involves reacting propene with hydrogen peroxide in the presence of methanol, a titanium zeolite epoxidation catalyst, and nitrogen containing compounds present in an amount of from 100 to 3000 mg/kg of hydrogen peroxide. Non-reacted propene is separated from the reaction mixture; the propene depleted reaction mixture is continuously distilled in a distillation column providing an overhead product stream containing propene oxide and methanol and a bottoms product stream; and propene oxide is separated from the overhead product stream. An acid is added to the propane depleted reaction mixture and/or to the distillation column at the same level or above the feed point for the propene depleted reaction mixture and/or contacted to the feed to the distillation column to provide an apparent pH in the bottoms product stream of from 3 to 4.5, which reduces the nitrogen content of the separated propene oxide.

Abstract: Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.

Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.

Abstract: A novel nano-sized 4-Bromo-2-[(9H-purin-6-ylimino)-methyl]-phenol imine Pd(II) complex, its synthesis, and its use for potential super pharmaceutical applications.

Abstract: A gel composition for treating bowel diseases comprising about 0.1 to about 2.5 wt. % of an anti-epileptic agent; about 0.8 to about 2.0% wt. % of a collagen complexed with a date palm extract of Khalas cultivar and carboxymethylcellulose; about 10 to about 50 ?g/mL of vanillic acid; about 0.1 to about 0.3 ?g of stearic acid; and water; wherein all wt. % are based on g/100 g of the gel composition. This gel composition can be topically administered to the rectum of a patient to treat one or more bowel diseases, disorders, or conditions.